pirenzepine has been researched along with Neuroleptic Malignant Syndrome in 38 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 8.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "We present a case of neuroleptic malignant syndrome in a 52-year-old patient who had been treated for 2(1/2) years with olanzapine, a new atypical antipsychotic agent." | 7.72 | [Neuroleptic malignant syndrome in a patient treated with olanzapine]. ( Horni, G; Lund, MB; Meirik, K, 2003) |
| " This resistant case of lethal catatonia responded selectively to high-dose olanzapine treatment." | 7.71 | Lethal catatonia responding to high-dose olanzapine therapy. ( Cassidy, EM; Finucane, J; O'Brien, M; O'Keane, V; Osman, MF, 2001) |
| "We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history." | 7.71 | Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. ( Gibson, B; Kang, N; Malyuk, R; Procyshyn, RM, 2002) |
| "To report a case of neuroleptic malignant syndrome (NMS) associated with the use of olanzapine." | 7.70 | Neuroleptic malignant syndrome associated with olanzapine. ( Billington, CJ; Ercan-Fang, N; Filice, GA; McDougall, BC, 1998) |
| "The aim of the present paper is to report a case of Neuroleptic Malignant Syndrome (NMS) occurring 2 days after olanzapine was added to the treatment regimen of an elderly patient with Schizoaffective Disorder." | 7.70 | Neuroleptic malignant syndrome associated with olanzapine. ( Bruxner, G; Johnson, V, 1998) |
| "To date only five reports of neuroleptic malignant syndrome (NMS) related to olanzapine exist." | 7.70 | Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. ( Järventausta, K; Leinonen, E, 2000) |
| "We present the case of a 42-year-old male with a history of schizophrenia who developed signs and symptoms consistent with Neuroleptic Malignant Syndrome (NMS) after 3 weeks of treatment with Olanzapine." | 7.70 | Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. ( Privette, T; Stanfield, SC, 2000) |
| "Classic neuroleptic malignant syndrome (NMS) was diagnosed." | 6.42 | Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. ( Berry, N; Gupta, SK; Pradhan, S; Sagar, R, 2003) |
| "Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders." | 6.42 | Olanzapine induced neuroleptic malignant syndrome--a case review. ( Kogoj, A; Velikonja, I, 2003) |
| "Olanzapine can cause NMS, mainly in susceptible or predisposed patients." | 6.41 | Olanzapine-associated neuroleptic malignant syndrome. ( Christodoulou, NG; Havaki-Kontaxaki, BJ; Kontaxakis, VP; Paplos, KG, 2002) |
| "A case of neuroleptic malignant syndrome (NMS) in a 23 year old male patient is reported." | 5.30 | [Neuroleptic malignant syndrome after treatment with olanzapine]. ( Emborg, C, 1999) |
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 4.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "We present a case of neuroleptic malignant syndrome in a 52-year-old patient who had been treated for 2(1/2) years with olanzapine, a new atypical antipsychotic agent." | 3.72 | [Neuroleptic malignant syndrome in a patient treated with olanzapine]. ( Horni, G; Lund, MB; Meirik, K, 2003) |
| " This resistant case of lethal catatonia responded selectively to high-dose olanzapine treatment." | 3.71 | Lethal catatonia responding to high-dose olanzapine therapy. ( Cassidy, EM; Finucane, J; O'Brien, M; O'Keane, V; Osman, MF, 2001) |
| "We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history." | 3.71 | Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. ( Gibson, B; Kang, N; Malyuk, R; Procyshyn, RM, 2002) |
| "To report a case of neuroleptic malignant syndrome (NMS) associated with the use of olanzapine." | 3.70 | Neuroleptic malignant syndrome associated with olanzapine. ( Billington, CJ; Ercan-Fang, N; Filice, GA; McDougall, BC, 1998) |
| "The aim of the present paper is to report a case of Neuroleptic Malignant Syndrome (NMS) occurring 2 days after olanzapine was added to the treatment regimen of an elderly patient with Schizoaffective Disorder." | 3.70 | Neuroleptic malignant syndrome associated with olanzapine. ( Bruxner, G; Johnson, V, 1998) |
| "To date only five reports of neuroleptic malignant syndrome (NMS) related to olanzapine exist." | 3.70 | Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. ( Järventausta, K; Leinonen, E, 2000) |
| "We present the case of a 42-year-old male with a history of schizophrenia who developed signs and symptoms consistent with Neuroleptic Malignant Syndrome (NMS) after 3 weeks of treatment with Olanzapine." | 3.70 | Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. ( Privette, T; Stanfield, SC, 2000) |
| "Classic neuroleptic malignant syndrome (NMS) was diagnosed." | 2.42 | Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. ( Berry, N; Gupta, SK; Pradhan, S; Sagar, R, 2003) |
| "Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders." | 2.42 | Olanzapine induced neuroleptic malignant syndrome--a case review. ( Kogoj, A; Velikonja, I, 2003) |
| "Olanzapine can cause NMS, mainly in susceptible or predisposed patients." | 2.41 | Olanzapine-associated neuroleptic malignant syndrome. ( Christodoulou, NG; Havaki-Kontaxaki, BJ; Kontaxakis, VP; Paplos, KG, 2002) |
| "Although the risk of developing lethal neuroleptic malignant syndrome may be diminished with atypical drugs, clinicians must remain alert to the signs of this disorder." | 2.41 | Movement disorders associated with atypical antipsychotic drugs. ( Campbell, EC; Caroff, SN; Mann, SC; Sullivan, KA, 2002) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| " The diagnosis of rhabdomyolysis was confirmed by myoglobinemia dosage and ortholuidine test." | 1.32 | [Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment]. ( Busiello, L; Cascella, M; De Robertis, E; Di Domenico, MG; Palmese, S; Pezza, M, 2003) |
| "A case of neuroleptic malignant syndrome (NMS) in a 23 year old male patient is reported." | 1.30 | [Neuroleptic malignant syndrome after treatment with olanzapine]. ( Emborg, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (39.47) | 18.2507 |
| 2000's | 23 (60.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ljubisavljevic, V | 1 |
| Ghaziuddin, N | 1 |
| Alkhouri, I | 1 |
| Champine, D | 1 |
| Quinlan, P | 1 |
| Fluent, T | 1 |
| Ghaziuddin, M | 1 |
| Kontaxakis, VP | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Christodoulou, NG | 1 |
| Paplos, KG | 1 |
| Hall, KL | 1 |
| Taylor, WH | 1 |
| Ware, MR | 1 |
| Goveas, JS | 1 |
| Hermida, A | 1 |
| Berry, N | 1 |
| Pradhan, S | 1 |
| Sagar, R | 1 |
| Gupta, SK | 1 |
| Suh, H | 1 |
| Bronson, B | 1 |
| Martin, R | 1 |
| Martí-Bonmatí, E | 1 |
| San Valero-Carcelén, E | 1 |
| Ortega-García, MP | 1 |
| Rubini-Puig, R | 1 |
| Kogoj, A | 1 |
| Velikonja, I | 1 |
| Kopf, A | 1 |
| Köster, J | 1 |
| Schulz, A | 1 |
| Krömker, H | 1 |
| Becker, T | 1 |
| Pezza, M | 1 |
| Busiello, L | 1 |
| Palmese, S | 1 |
| Cascella, M | 1 |
| Di Domenico, MG | 1 |
| De Robertis, E | 1 |
| Horni, G | 1 |
| Meirik, K | 1 |
| Lund, MB | 1 |
| Casey, DE | 1 |
| Filice, GA | 1 |
| McDougall, BC | 1 |
| Ercan-Fang, N | 1 |
| Billington, CJ | 1 |
| Moltz, DA | 1 |
| Coeytaux, RR | 1 |
| Burkhard, PR | 1 |
| Vingerhoets, FJ | 1 |
| Alberque, C | 1 |
| Landis, T | 1 |
| Hanel, RA | 1 |
| Sandmann, MC | 1 |
| Kranich, M | 1 |
| De Bittencourt, PR | 1 |
| Johnson, V | 1 |
| Bruxner, G | 1 |
| Emborg, C | 1 |
| Hickey, C | 1 |
| Stewart, C | 1 |
| Lippmann, S | 1 |
| Margolese, HC | 1 |
| Chouinard, G | 1 |
| García López, MM | 1 |
| Ciprés, L | 1 |
| de Cendra, E | 1 |
| Vilalta Franch, J | 1 |
| Hammond, C | 1 |
| Haggarty, JM | 1 |
| Husni, M | 1 |
| Peat, C | 1 |
| Allain, S | 1 |
| Levenson, JL | 1 |
| Gheorghiu, S | 1 |
| Knobler, HY | 1 |
| Drumer, D | 1 |
| Gram, LF | 1 |
| Kohen, D | 1 |
| Bristow, MF | 1 |
| Nyfort-Hansen, K | 1 |
| Alderman, CP | 1 |
| Järventausta, K | 1 |
| Leinonen, E | 1 |
| Canora Lebrato, J | 1 |
| Bermúdez García, JM | 1 |
| Alvarez García, ML | 1 |
| Rico Irles, J | 1 |
| Stanfield, SC | 1 |
| Privette, T | 1 |
| Sierra-Biddle, D | 1 |
| Herran, A | 1 |
| Diez-Aja, S | 1 |
| Gonzalez-Mata, JM | 1 |
| Vidal, E | 1 |
| Diez-Manrique, F | 1 |
| Vazquez-Barquero, JL | 1 |
| Mujica, R | 1 |
| Weiden, P | 1 |
| Cassidy, EM | 1 |
| O'Brien, M | 1 |
| Osman, MF | 1 |
| Finucane, J | 1 |
| O'Keane, V | 1 |
| Caroff, SN | 1 |
| Mann, SC | 1 |
| Campbell, EC | 1 |
| Sullivan, KA | 1 |
| Malyuk, R | 1 |
| Gibson, B | 1 |
| Procyshyn, RM | 1 |
| Kang, N | 1 |
| Reeves, RR | 1 |
| Torres, RA | 1 |
| Liberto, V | 1 |
| Hart, RH | 1 |
7 reviews available for pirenzepine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Olanzapine-associated neuroleptic malignant syndrome.
Topics: Benzodiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Retrospective Stud | 2002 |
Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Differential; Drug T | 2003 |
Olanzapine induced neuroleptic malignant syndrome--a case review.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepi | 2003 |
[Life threatening neuroleptic malignant syndrome due to olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol | 2003 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
[Neuroleptic malignant syndrome associated with olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Ol | 1999 |
Movement disorders associated with atypical antipsychotic drugs.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 2002 |
31 other studies available for pirenzepine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Lethal catatonia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Catatonia; Diagnosis, Differential; Electroconvulsive | 2002 |
ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment.
Topics: Adolescent; Benzodiazepines; Brain; Catatonia; Diagnosis, Differential; Diagnostic Imaging; Electroc | 2002 |
Neuroleptic malignant syndrome due to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Neuroleptic Malignant Syndrome; Olanza | 2001 |
Olanzapine induced "typical" neuroleptic malignant syndrome.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dopamine; Humans; Male; Neuroleptic M | 2003 |
Neuroleptic malignant syndrome and low-dose olanzapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Dose-Response Relationship | 2003 |
Olanzapine elevation of serum creatine kinase.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Creatine Kinase, MB Form; Diagnosis, | 2003 |
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].
Topics: Acute Kidney Injury; Adult; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Fever; H | 2003 |
[Neuroleptic malignant syndrome in a patient treated with olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Ol | 2003 |
Neuroleptic malignant syndrome associated with olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Male; Neuroleptic Malignant S | 1998 |
Case report: possible neuroleptic malignant syndrome associated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Neuroleptic Malignant Syndrome; Olanza | 1998 |
Olanzapine-induced neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Pi | 1999 |
[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Haloperidol; Humans; Male; Neuroleptic | 1998 |
Neuroleptic malignant syndrome associated with olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Humans; Male; Neuroleptic Mali | 1998 |
[Neuroleptic malignant syndrome after treatment with olanzapine].
Topics: Adult; Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Clozapine; Drug Synergism; Humans; | 1999 |
Olanzapine and NMS.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapi | 1999 |
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Humans; Intellectual Disability; Male; Me | 1999 |
Finding drug link to reaction.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Benzodiazepines; Humans; Neuroleptic | 1999 |
Atypical neuroleptic malignant syndrome?
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Ol | 1999 |
Neuroleptic malignant syndrome after the initiation of olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; | 1999 |
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chlorprothixene; Clopenthixol; Female | 1999 |
[Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Neuroleptic Mal | 2000 |
Atypical antipsychotics and neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Neuroleptic Malignant Syndrome; O | 1999 |
Possible neuroleptic malignant syndrome associated with olanzapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Fever; Humans; Male; Mental Disorder | 2000 |
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Humans; Methotrimeprazine; Neu | 2000 |
[Neuroleptic malignant syndrome and atypical antipsychotics].
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapin | 2000 |
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Benzodiazepines; Bromocriptine; Combined Modalit | 2000 |
Neuropletic malignant syndrome and olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Neuroleptic Malignant Syndrome; Olanza | 2000 |
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Se | 2001 |
Lethal catatonia responding to high-dose olanzapine therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Catatonia; Electroconvulsive Therapy | 2001 |
Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Middle Aged; Neuroleptic Malig | 2002 |
Atypical neuroleptic malignant syndrome associated with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Cell Count; Hallucinations; Humans; Male; Middle Aged; | 2002 |